Elise Chong, MD, assistant professor of medicine at the Abramson Cancer Center at the University of Pennsylvania, discusses her oral abstract session, “Outcomes of liso-cel in R/R MCL: First real-world data from the CIBMTR,” which was presented at the SOHO 2026 Annual Meeting.
The study evaluated registry data from a heavily pretreated cohort to assess the CAR T-cell therapy’s performance outside of clinical trials. The findings demonstrated high overall response rates and safety profiles consistent with the pivotal TRANSCEND trial.
“…This represents… the first real-world data,” she said. “It’s also actually the largest cohort of liso-cel-treated patients with mantle cell lymphoma that’s been reported…”
Leave feedback about this